Anemia, Iron-Deficiency ; prevention & control ; therapy ; Child ; Humans ; Iron ; deficiency

Humans ; Anemia, Iron-Deficiency/therapy* ; Iron Deficiencies ; Iron/therapeutic use*

Anemia, Iron-Deficiency ; prevention & control ; therapy ; Child ; Humans

Ferric carboxymaltose is a non-dextran?iron complex used in patients with iron deficiency. However, iron injections may lead to long-lasting brown discoloration secondary to extravasation at the injection site. We herein report a case involving a patient who developed pigmentation after intravenous iron injection and was successfully treated with combined laser therapy. A 36-year-old woman presented with circumscript pigmentation on her left arm after having undergone intravenous iron injection for the treatment of iron deficiency anemia. Histopathologic examination revealed basal hypermelanosis and dermal infiltration of siderophages. Combined therapy with 1064 nm Nd:YAG laser and 595 nm pulsed dye laser was performed to treat the lesion, and marked improvement was noted after five sessions.
Adult ; Anemia, Iron-Deficiency ; Arm ; Female ; Humans ; Hyperpigmentation ; Iron Compounds ; Iron* ; Laser Therapy ; Lasers, Dye* ; Pigmentation*

Ferric carboxymaltose is a non-dextran?iron complex used in patients with iron deficiency. However, iron injections may lead to long-lasting brown discoloration secondary to extravasation at the injection site. We herein report a case involving a patient who developed pigmentation after intravenous iron injection and was successfully treated with combined laser therapy. A 36-year-old woman presented with circumscript pigmentation on her left arm after having undergone intravenous iron injection for the treatment of iron deficiency anemia. Histopathologic examination revealed basal hypermelanosis and dermal infiltration of siderophages. Combined therapy with 1064 nm Nd:YAG laser and 595 nm pulsed dye laser was performed to treat the lesion, and marked improvement was noted after five sessions.
Adult ; Anemia, Iron-Deficiency ; Arm ; Female ; Humans ; Hyperpigmentation ; Iron Compounds ; Iron* ; Laser Therapy ; Lasers, Dye* ; Pigmentation*

OBJECTIVE: To observe and compare the therapeutic effects of hydroxypropyl chitosan ferrous ion complex solution and ferrous sulfate solution in iron deficiency anemia rats and their effects on gastric mucosa. METHODS: Seven rats were randomly selected from thirty five SPF grade SD rats as control group, and were fed with normal diet, distilled water (E). The rest of SD rats were fed with low iron feed and distilled water plus continuous tail vein bloodletting to establish the iron deficiency anemia model. After the model was established successfully, the rats were randomly divided into four groups: blank control group (A), iron deficiency anemia control group (B), ferrous sulfate group (C), hydroxypropyl chitosan ferrous ion complex (HPCTS-Fe RESULTS: After modeling, except the normal control group, the hair color of the rats in the four groups showed dark yellow and the belly of the toes became white gradually. HGB, HCT, Ret%, MCV, MCH, MCHC and SF decreased significantly (P < 0.05). After treatment, the rats with dark yellow hair in group C and D were improved, and the toe abdomen turned pink gradually. RBC, HGB, HCT, Ret%, MCV, MCH, MCHC and SF in rats in group C and D increased, which were higher than those in group B (P < 0.05). The HGB of the rats in group D was higher than that of group C in day 28th during treatment and the Ret% was higher than that in group C at day 10th (P<0.05).After treatment, the liver and spleen of the rats in group C and D were lighter than those in group B (P<0.05).The gastric mucosa in group A, B, D and E was not damaged obviously, while it was slightly irritated and damaged in group C. CONCLUSION Hydroxypropyl chitosan ferrous complex solution can improve the hemoglobin level of SD rats with iron deficiency anemia, which is stronger than ferrous sulfate solution and shows no damage to gastric mucosa.
Anemia, Iron-Deficiency/drug therapy* ; Animals ; Chitosan ; Ferrous Compounds ; Hemoglobins ; Iron ; Rats ; Rats, Sprague-Dawley

OBJECTIVES: We attempt to find out the decremental character of serum vitamin B12 level and features of patients with vitamin B12 deficiency anemia occurring earlier than 4 years after total gastrectomy. Methods: We studied 91 patients who underwent total gastrectomy and select 59 patients who evaluate serum vitamin B12 level within 4 years after total gastrectomy to characterize the features of vitamin B12 deficiency anemia group occurring earlier than 4 years after the operation. RESULTS: 1) In 91 patients, the mean postoperative duration is 31.9(range: 0-135) months and mean serum vitamin B12 level 158.9(total 159 times, range: 20.0-806.2) pg/mL. Correlation equation is y=403.30 x e-0.09x+175.93 x e-0.02 x (r2=0.804). The postoperation duration that serum vitamin B12 level falls below 200 pg/mL is 20 months. 2) Among 59 patients, there were 20 cases of vitamin B12 deficiency anemia group(Group I), 21 cases of vitamin B12 deficiency(Group II) and 39 cases of non-vitamin B12 deficiency group(Group III). Preoperation symptom dura tion in Group I was longer than that in Group II(18.2 vs 9.6 weeks, p<0.01). Group I and Group II showed lower serum vitamin B12 level than Group III(126.7 & 96.0 pg/mL vs 330.4 pg/mL, p<0.01). 3) Eleven cases had associated diseases(9 alcoholics and 2 liver cirrhosis) with vitamin B12 deficiency anemia and these disease had significant influence on the incidence of vitamin B12 deficiency anemia(p<0.01) within 4 years. Among the 30 cases who could measure iron profile, 10 patients had an iron deficiency anemia. There was a higher incidence of vitamin B12 deficiency anemia in iron deficiency anemia group(7/10, 70%) than that in non iron deficiency anemia group(7/20, 35%) but no sta tistical significance(p=0.12). 4) Although anti-cancer chemotherapy did not have a significant influence on the incidence of vitamin B12 defi ciency anemia, vitamin B12 level in anti-cancer chemo therapy group was higher than that in non-chemotherapy group(201.83 vs 127.66 pg/mL, p=0.01) at similar mean postoperation duration(27.8 vs 27.7 months, p=0.97). 5) The independent predictor of vitamin B12 deficiency anemia within 4 years were associated disease(p=0.002) and preoperation symptom duration(p=0.004). CONCLUSION: Red cell indices such as Hb or MCV did not have any clinical significances in predicting the development of vitamin B12 deficiency. To prevent vitamin B12 deficiency anemia and promote better quality of life in total gastrectomized patients with stomach can cer, careful monitoring of serum vitamin B12 level and re placement therapy should be necessary at least 20 months after operation, especially in patients with associated disease and longer preoperation symptom duration.
Alcoholics ; Anemia ; Anemia, Iron-Deficiency ; Drug Therapy ; Erythrocyte Indices ; Gastrectomy* ; Humans ; Incidence ; Iron ; Liver ; Quality of Life ; Stomach Neoplasms* ; Stomach* ; Vitamin B 12 Deficiency* ; Vitamin B 12* ; Vitamins*

OBJECTIVE: To compare the clinical efficacy and safety of oral administration of Buxue Yimu Pills (BYP, ), ferrous sulfate (FS), and the combination of BYP and FS on gynecological anemia, and investigate the mechanisms using network pharmacology. METHODS: A randomized, controlled, multi-center clinical trial was conducted. Totally 150 patients with hemoglobin of 70-110 g/L due to gynecological conditions were recruited and randomized (using the block randomization method) into Buxue Yimu Pills group (24 g/d), oral iron group (FS Tablets, 0.9 g/d), and combined treatment group (BYP, 24 g/d plus FS Tablets, 0.9 g/d), 50 patients in each group. At the enrollment and 4-week treatment, complete blood count, serum iron indexes were evaluated. Adverse events, liver and renal functions, as well as blood coagulation were observed. Network pharmacology was conducted to identify the active ingredients and explore the potential mechanisms of BYP. RESULTS: Ten (20%) and 7 (14%) participants discontinued the therapy due to gastrointestinal symptoms in oral iron and combination treatment groups. All 3 groups showed elevated hemoglobin. The patients in the iron group exhibited typically elevated in serum iron and ferritin and decreased in total iron-binding capacity. No change in iron indexes was observed in BYP group. The patients in the combination treatment group neither showed significant changes in serum ferritin nor total iron-binding capacity. No significant adverse reactions were observed in the BYP group. The network pharmacology identified 27 bioactive compounds and 145 targets of BYP on gynecological anemia. Biological processes and pathways including regulation of inflammation, hormone, angiogenesis and hemostasis, response to decreased oxygen levels, effects on myeloma cell, and response to metal ions were identified. CONCLUSION BYP contributes to the practical improvement on gynecological anemia potentially through multi-target mechanisms and optimized iron re-distribution. (Trial registration: No. NCT03232554).
Humans ; Anemia/drug therapy* ; Anemia, Iron-Deficiency/drug therapy* ; Ferritins/therapeutic use* ; Hemoglobins ; Iron/therapeutic use* ; Network Pharmacology ; Drugs, Chinese Herbal

Watermelon stomach or gastric antral vascular ectasia is a rare disorder causing gastric blood loss and iron deficicncy anemia. Endoscopically, it has characteristic thickened red vascular folds radiating from the pylorus to the antrum. This condition is often mis- diagnosed as antral hemorrhagic gastritis. Diagnosis is made primarily by endoscopy. Histologic examination of the endoscopic mucosal biopsies may confirm the endoscopic diagnosis. Treatment for watermelon stomach includes steroids, estrogen-progesterone combinations, somatostatin antagonists, tranexamic acid, heater probe, and laser therapy. Herein we report a case of watermelon stomach presenting with general weakness and persistent iron deficiency anemia for about 2 years in a 70-year-old woman.
Aged ; Anemia ; Anemia, Iron-Deficiency ; Biopsy ; Citrullus* ; Diagnosis ; Endoscopy ; Female ; Gastric Antral Vascular Ectasia* ; Gastritis ; Humans ; Iron ; Laser Therapy ; Pylorus ; Somatostatin ; Steroids ; Tranexamic Acid

BACKGROUND: Iron deficiency anemia is the most common form of anemia in India. Hemoglobin A1c (HbA1c) is used in diabetic patients as an index of glycemic control reflecting glucose levels of the previous 3 months. Like blood sugar levels, HbA1c levels are also affected by the presence of variant hemoglobins, hemolytic anemias, nutritional anemias, uremia, pregnancy, and acute blood loss. However, reports on the effects of iron deficiency anemia on HbA1c levels are inconsistent. We conducted a study to analyze the effects of iron deficiency anemia on HbA1c levels and to assess whether treatment of iron deficiency anemia affects HbA1c levels. METHODS: Fifty patients confirmed to have iron deficiency anemia were enrolled in this study. HbA1c and absolute HbA1c levels were measured both at baseline and at 2 months after treatment, and these values were compared with those in the control population. RESULTS: The mean baseline HbA1c level in anemic patients (4.6%) was significantly lower than that in the control group (5.5%, p<0.05). A significant increase was observed in the patients' absolute HbA1c levels at 2 months after treatment (0.29 g/dL vs. 0.73 g/dL, p<0.01). There was a significant difference between the baseline values of patients and controls (0.29 g/dL vs. 0.74 g/dL, p<0.01). CONCLUSIONS: In contrast to the observations of previous studies, ours showed that HbA1c levels and absolute HbA1c levels increased with treatment of iron deficiency anemia. This could be attributable to nutritional deficiency and/or certain unknown variables. Further studies are warranted.
Adolescent ; Adult ; Anemia, Iron-Deficiency/*blood/drug therapy ; Child ; Female ; Ferritins/blood ; Hemoglobin A, Glycosylated/*analysis ; Hemoglobins/analysis ; Humans ; Iron/therapeutic use ; Male ; Time Factors